Unauthorized

Digital Therapeutics (DTx) entered the discourse of digital health nearly a decade ago but have yet to reach a broad consumer market due to lack of mature payment models and support from PBMs. The mainstreaming of DTx at the consumer level still has a distance to go to reach mainstream consumers and lack of payment models is one of the primary constraints.